Patents Assigned to Dendritic Nanotechnologies, Inc.
  • Patent number: 10981858
    Abstract: The present invention relates to a novel dendrimer. The present invention also relates to formulations comprising the dendrimer with improved characteristics. For instance, the present invention relates to formulations comprising pesticides such as 2-(2,4-dichlorophenoxy)acetic acid with improved characteristics such as reduced crystallisation, compatibility with hard water and an extended shelf life at low temperatures.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: April 20, 2021
    Assignees: Priostar Pty Ltd, Dendritic Nanotechnologies, Inc.
    Inventors: Harsh Vardhan, Sarigama Rajesh, Peter Karellas
  • Publication number: 20110230348
    Abstract: Specific PEHAM dendrimers are used in a formulation with an active agent for agricultural purposes, particularly for increasing the efficacy of the active agent in various ways, such as by improving solubility of the active agent in the formulation, by improving adhesion and penetration of the active agent to plant surfaces, by improving the water-fastness of the active agent to the plant or seed, by increasing soil penetration of the active agent to reach the plant roots or under soil parts, or by reducing soil adhesion of the active agent to reach the plant roots or under soil parts, or reducing enzymatic degradation of the active agent by the plant or seed or microorganisms in the soil.
    Type: Application
    Filed: May 4, 2011
    Publication date: September 22, 2011
    Applicants: Dendritic Nanotechnologies, Inc., Starpharma Pty Ltd
    Inventors: Ryan T. Hayes, David James Owen, Abhay Singh Chauhan, Veera Reddy Pulgam
  • Patent number: 7985424
    Abstract: Dendritic polymers with enhanced amplification and interior functionality are disclosed. These dendritic polymers are made by use of fast, reactive ring-opening chemistry (or other fast reactions) combined with the use of branch cell reagents in a controlled way to rapidly and precisely build dendritic structures, generation by generation, with cleaner chemistry, often single products, lower excesses of reagents, lower levels of dilution, higher capacity method, more easily scaled to commercial dimensions, new ranges of materials, and lower cost. The dendritic compositions prepared have novel internal functionality, greater stability (e.g., thermal stability and less or no reverse Michael's reaction), and reach encapsulation surface densities at lower generations. Unexpectedly, these reactions of polyfunctional branch cell reagents with polyfunctional cores do not create cross-linked materials.
    Type: Grant
    Filed: December 21, 2005
    Date of Patent: July 26, 2011
    Assignee: Dendritic Nanotechnologies Inc.
    Inventors: Donald A. Tomalia, Douglas R. Swanson, Baohua Huang, Veera Reddy Pulgam, Joseph R. Heinzelmann, Sonke Svenson, Lori A. Reyna, Michael A. Zhuravel, Abhay Singh Chauhan, Cordell R. DeMattei
  • Patent number: 7981444
    Abstract: Poly(ester-acrylate) and poly(ester/epoxide) dendrimers. These materials can be synthesized by utilizing the so-called “sterically induced stoichiometric” principles. The preparation of the dendrimers is carried out by reacting precursor amino/polyamino-functional core materials with various branch cell reagents. The branch cell reagents are dimensionally large, relative to the amino/polyamino-initiator core and when reacted, produce generation=1 dendrimers directly in one step. There is also a method by which the dendrimers can be stabilized and that method is the reaction of the dendrimers with surface reactive molecules to pacify the reactive groups on the dendrimers.
    Type: Grant
    Filed: April 20, 2005
    Date of Patent: July 19, 2011
    Assignee: Dendritic Nanotechnologies, Inc.
    Inventors: Donald A. Tomalia, Douglas R. Swanson, Baohua Huang, Veera Reddy Pulgam
  • Patent number: 7977452
    Abstract: This invention provides a cost effective process and new Janus dendrimers where at least two dendrons are attached at the core (with or without a connector group) and where at least two of the dendrons have different functionality. Preferred are those Janus dendrimers where at least one dendron is a PEHAM dendron. Thus these Janus dendrimers are heterobifunctional in character and use unique ligation chemistry with single site functional dendrons, di-dendrons and multi-dendrons. Also included are Janus dendrons which may be used as intermediates to make the Janus dendrimers or to further react with another reactive moiety.
    Type: Grant
    Filed: March 27, 2006
    Date of Patent: July 12, 2011
    Assignee: Dendritic Nanotechnologies, Inc.
    Inventors: Donald A. Tomalia, Veera Reddy Pulgam, Douglas R. Swanson, Boahua Huang
  • Publication number: 20100086482
    Abstract: The present invention describes a process for preparing new looped dendrimer and dendron compounds by controlling the molar amount of branch cell reagent monomer that is combined with various cores bearing core-XR functionalities (e.g., primary, or secondary amines, thiol, or epoxy functionalities). These looped, macrocyclic structures are more robust to various conditions, with greater resistance to acid/base hydrolysis. Alternatively, the looped, macrocyclic structure may offer new orientations that would qualify it as a better chelation ligand for metals, and other similar uses.
    Type: Application
    Filed: December 28, 2007
    Publication date: April 8, 2010
    Applicant: Dendritic Nanotechnologies, Inc.
    Inventors: Donald A. Tomalia, Douglas R. Swanson, Baohua Huang, Veera Reddy Pulgam
  • Publication number: 20080112891
    Abstract: An encapsulated chelate dendritic polymer and an encapsulated ligand dendritic polymer are disclosed which have unique properties. These encapsulated chelate dendritic polymers may have associated with its dendritic polymer surface target directors, proteins, DNA, RNA (including single strands) or any other moieties that will assist in diagnosis, therapy or delivery of this encapsulated chelate dendritic polymer. These encapsulated dendritic polymers are suitable as contrast agents for use in imaging in an animal, for other imaging techniques, for EPR, and as scavenger agents for chelant therapy. Formulations for these uses are also included within the scope of this invention.
    Type: Application
    Filed: February 15, 2006
    Publication date: May 15, 2008
    Applicant: Dendritic Nanotechnologies, Inc.
    Inventors: Donald A. Tomalia, Baohua Huang
  • Publication number: 20070298006
    Abstract: Dendritic polymers with enhanced amplification and interior functionality are disclosed. These dendritic polymers are made by use of fast, reactive ring-opening chemistry (or other fast reactions) combined with the use of branch cell reagents in a controlled way to rapidly and precisely build dendritic structures, generation by generation, with cleaner chemistry, often single products, lower excesses of reagents, lower levels of dilution, higher capacity method, more easily scaled to commercial dimensions, new ranges of materials, and lower cost. The dendritic compositions prepared have novel internal functionality, greater stability (e.g., thermal stability and less or no reverse Michael's reaction), and reach encapsulation surface densities at lower generations. Unexpectedly, these reactions of polyfunctional branch cell reagents with polyfunctional cores do not create cross-linked materials.
    Type: Application
    Filed: December 21, 2005
    Publication date: December 27, 2007
    Applicant: Dendritic Nanotechnologies, Inc.
    Inventors: Donald Tomalia, Douglas Swanson, Baohua Huang, Veera Pulgam, Sonke Svenson, Lori Reyna, Michael Zhuravel, Abhay Chauhan, Cordell DeMattei, Joseph Heinzelmann
  • Publication number: 20070244296
    Abstract: Poly(ester-acrylate) and poly(ester/epoxide) dendrimers. These materials can be synthesized by utilizing the so-called “sterically induced stoichiometric” principles. The preparation of the dendrimers is carried out by reacting precursor amino/polyamino-functional core materials with various branch cell reagents. The branch cell reagents are dimensionally large, relative to the amino/polyamino-initiator core and when reacted, produce generation=1 dendrimers directly in one step. There is also a method by which the dendrimers can be stabilized and that method is the reaction of the dendrimers with surface reactive molecules to pacify the reactive groups on the dendrimers.
    Type: Application
    Filed: April 20, 2005
    Publication date: October 18, 2007
    Applicant: Dendritic Nanotechnologies, Inc.
    Inventors: Donald Tomalia, Douglas Swanson, Baohua Huang, Veera Pulgam
  • Publication number: 20070073004
    Abstract: Methods of providing hyperbranched polymers by polymerization of appropriate AB2 monomers derived from the reaction of tris-(2-aminoethyl) amine and various other materials, namely, succinic anhydride, methyl acrylate, and dimethyl ita-conate.
    Type: Application
    Filed: September 10, 2004
    Publication date: March 29, 2007
    Applicant: DENDRITIC NANOTECHNOLOGIES INC.
    Inventors: Donald Tomalia, Douglas Swanson
  • Publication number: 20060177376
    Abstract: Dendronization of nano-scale surfaces with focal point reactive dendrons to produce stabilized chemically functionalized nano-particles having quantum dot dimensions.
    Type: Application
    Filed: July 21, 2004
    Publication date: August 10, 2006
    Applicant: Dendritic Nanotechnologies, Inc.
    Inventors: Donald Tomalia, Boahua Huang
  • Patent number: 7005124
    Abstract: Antineoplastic dendritic polymer conjugates which are useful drug delivery systems for carrying antineoplastic agents to malignant tumors are prepared by obtaining a dendritic polymer having functional groups which are accessible to an antineoplastic agent capable of interacting with the functional groups, and contacting the dendritic polymer with the antineoplastic agent. The preferred platin-based analogues of the antineoplastic agents conjugated to the dendritic polymer may be administered intravenously, orally, parentally, subcutaneously, intramuscularly, intraarterially or topically to an animal having a malignant tumor in an amount which is effective to inhibit growth of the malignant tumor. The antineoplastic dendritic polymer conjugates exhibit high drug efficiency, high drug carrying capacity, good water solubility, good stability on storage, reduced toxicity, and improved anti-tumor activity in vivo.
    Type: Grant
    Filed: October 29, 2001
    Date of Patent: February 28, 2006
    Assignee: Dendritic Nanotechnologies, Inc.
    Inventors: Navid Malik, Ruth Duncan, Donald A. Tomalia, Roseita Esfand